NCT06275373View on ClinicalTrials.gov

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

May 12, 2021

Primary Completion Date

May 12, 2026

Study Completion Date

December 12, 2027

Conditions
Thyroid Eye DiseaseGraves OphthalmopathyGraves Disease
Interventions
DRUG

Teprotumumab Injection [Tepezza]

IGF1 monoclonal antibody

Trial Locations (1)

20889

RECRUITING

Walter Reed National Military Medical Center, Bethesda

All Listed Sponsors
lead

Walter Reed National Military Medical Center

FED